Replies to post #141181 on Biotech Values

[DewDiligence]

PLX—Think there's a very good chance of bypassing Vpriv EU exclusivity.

Why? T.i.a.

I’m not working undercover for Shire :- )

[ghmm]

Do you or perhaps jq know how Replagal and Fabrazyme both got on the market in the EU but Genzyme beat TKT in the US and through Orphan drug there kept them off the market? (Thats when I became a shareholder in TKT)